Amneal Pharmaceuticals, Inc. (AMRX): who owns it and who trades it
As of Nov 16, 2026, AMRX insiders reported 6 open-market sales worth $8.3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason B. Daly (Vice president), with $3.8M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Amneal Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AMRX
305 funds and institutions reported AMRX shares worth $2.9B at the end of Q2 2026, about 53% of the company. The largest holder is BlackRock, Inc. with 8.3%.
Funds and institutions (13F) 53%Everyone else 47%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 26.56M | 8.33% | $460M | +8% |
| Tpg Gp A, LLC | 12.33M | 3.86% | $213M | No change |
| Vanguard Portfolio Management LLC | 12.14M | 3.80% | $210M | +7% |
| Rubric Capital Management LP | 10.17M | 3.19% | $176M | -8% |
| Vanguard Capital Management LLC | 7.71M | 2.42% | $133M | +2% |
| State Street Corp | 7.36M | 2.31% | $127M | +8% |
| Dimensional Fund Advisors LP | 5.79M | 1.82% | $100M | +2% |
| Geode Capital Management, LLC | 5.14M | 1.61% | $89M | +13% |
| Assenagon Asset Management S.A. | 4.89M | 1.53% | $84.7M | +59% |
| Nantahala Capital Management, LLC | 4.54M | 1.42% | $78.5M | +60% |
| Morgan Stanley | 4.11M | 1.29% | $71.1M | -11% |
| Neuberger Berman Group LLC | 3.89M | 1.22% | $67.3M | +6% |
| Invesco Ltd. | 3.50M | 1.10% | $60.6M | +10% |
| Nuveen, LLC | 3.32M | 1.04% | $57.6M | +3% |
| Allspring Global Investments Holdings, LLC | 3.30M | 1.03% | $55.9M | +29% |
| Goldman Sachs Group Inc | 3.01M | 0.94% | $52.2M | +5% |
| Charles Schwab Investment Management Inc | 2.15M | 0.67% | $37.2M | -2% |
| Sixth Street Partners Management Company, L.P. | 2.15M | 0.67% | $37.2M | – |
| Northern Trust Corp | 1.91M | 0.60% | $33.1M | +12% |
| Acadian Asset Management LLC | 1.65M | 0.52% | $28.6M | -15% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AMRX insiders reported $0 of open-market purchases and $8.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | John Kiely | Director | Sale | 50,000 | $17.64 | $882K | Form 4 |
| Aug 12, 2026 | Nikita Shah | Vice president | Sale | 146,403 | $17.51 | $2.6M | Form 4 |
| Aug 12, 2026 | Jason B. Daly | Vice president | Sale | 210,000 | $17.40 | $3.7M | Form 4 |
| Aug 11, 2026 | Jason B. Daly | Vice president | Sale | 6,613 | $17.70 | $117K | Form 4 |
| May 11, 2026 | Deborah M. Autor | Director | Sale | 34,819 | $12.94 | $451K | Form 4 |
| Nov 17, 2025 | Ted C Nark | Director | Sale | 50,000 | $11.72 | $586K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jason B. Daly | EVP, Chief Legal Officer | – | $3.8M | Aug 12, 2026 |
| Nikita Shah | Executive Vice President | – | $2.6M | Aug 12, 2026 |
| John Kiely | Director | – | $882K | Aug 13, 2026 |
| Ted C Nark | Director | – | $586K | Nov 17, 2025 |
| Deborah M. Autor | Director | – | $451K | May 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AMRX short interest
Low short interest. 3.3% of AMRX shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went up 43%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.39M AMRX shares were sold short, 3.3% of the shares outstanding, down 19.0% from the report before. At the average daily volume of 4.09M shares, buying them all back would take about 2.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.39M | 3.27% | -19% | 4.09M | 2.8 |
| Oct 15, 2026 | 14.07M | 4.41% | +25% | 3.81M | 3.7 |
| Sep 30, 2026 | 11.28M | 3.53% | -0% | 3.69M | 3.1 |
| Sep 15, 2026 | 11.29M | 3.54% | +7% | 1.70M | 6.6 |
| Aug 31, 2026 | 10.57M | 3.31% | +11% | 1.43M | 7.4 |
| Aug 14, 2026 | 9.51M | 2.98% | +14% | 1.95M | 4.9 |
| Jul 31, 2026 | 8.32M | 2.61% | +2% | 1.82M | 4.6 |
| Jul 15, 2026 | 8.12M | 2.54% | +4% | 1.80M | 4.5 |
| Jun 30, 2026 | 7.84M | 2.46% | -1% | 2.71M | 2.9 |
| Jun 15, 2026 | 7.92M | 2.48% | +5% | 2.04M | 3.9 |
| May 29, 2026 | 7.53M | 2.36% | -5% | 1.62M | 4.6 |
| May 15, 2026 | 7.96M | 2.50% | -31% | 1.48M | 5.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Amneal Pharmaceuticals company events
Amneal Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 10, 2026DealThe information set forth in the Introductory Note of this Report is incorporated into this Item 2.01 by reference. Filing
- Aug 3, 2026AgreementAmneal Pharmaceuticals, Inc.’s subsidiary, Amneal Pharmaceuticals LLC, and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 3 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto… Filing
- Jul 31, 2026VoteReported shareholder vote results. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- May 7, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 22, 2026AgreementAmneal Pharmaceuticals, Inc., a Delaware corporation, entered into a Membership Interest Purchase Agreement with Kashiv BioSciences, LLC, KB Seller Representative, LLC and the equityholders of Kashiv named therein, pursuant to which, among other matters and on the terms and subject to the… Filing
- Feb 27, 2026ResultsReleased financial results. Filing
- Feb 3, 2026AgreementAmneal Pharmaceuticals, Inc.’s subsidiary, Amneal Pharmaceuticals LLC, and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto… Filing
- Jan 28, 2026AnnouncementAmneal Pharmaceuticals, Inc. determined that it will make effective its nationwide agreement to settle a substantial majority of the opioids-related claims brought against the Company by various states and subdivisions, having previously secured sufficient participation by those states and… Filing
- Jan 13, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Amneal Pharmaceuticals financials
Famous investors that hold AMRX
2 of the 50 well-known investors we track reported holding AMRX in their latest 13F filing. The largest position is Ken Griffin's, worth $141M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 6.99M | $141M | 0.1% | +525% |
| Israel Englander · Millennium Management | Q3 2026 | 294,727 | $5.9M | 0.0% | +1897% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Amneal Pharmaceuticals, Inc. (AMRX) stock
Who owns the most AMRX stock?
The largest reported owner of Amneal Pharmaceuticals, Inc. (AMRX) is BlackRock, Inc., with 8.3% of the company. In total, 305 funds and institutions reported holding AMRX at the end of Q2 2026, together about 53% of the shares. See the largest owners.
Are AMRX insiders buying or selling?
In the last 12 months, AMRX insiders reported no open-market purchases and 6 sales worth $8.3M. The latest trade was on Aug 13, 2026. See every trade.
What is the short interest in AMRX?
As of Oct 30, 2026, 11.39M AMRX shares were sold short, 3.3% of the shares outstanding, down 19.0% from the report before. At the average daily volume of 4.09M shares, buying them all back would take about 2.8 trading days (days to cover). See the history.
Which famous investors hold AMRX?
2 of the 50 well-known investors we track reported AMRX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $141M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.